Dubroff Jacob G, Hsieh Chia-Ju, Wiers Corinde E, Lee Hsiaoju, Schmitz Alexander, Li Elizabeth J, Schubert Erin K, Mach Robert H, Kranzler Henry R
Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;
Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
J Nucl Med. 2025 Jul 1;66(7):1112-1118. doi: 10.2967/jnumed.124.269413.
μ-opioid receptors (MORs) are G-coupled receptors widely expressed in the brain and body. MORs have a high affinity for both endogenous opioids such as β-endorphins and exogenous opioids such as fentanyl. They mediate pain and reward and have been implicated in the pathophysiology of opioid, cocaine, and other substance use disorders. Using an instrument with a long axial field of view and the MOR-selective radioligand [C]carfentanil, we measured the whole-body distribution of MORs in 13 healthy humans. We also examined sex differences in MOR distribution at baseline and after pretreatment with the MOR antagonist naloxone. Six female and 7 male healthy subjects underwent 2 [C]carfentanil PET imaging sessions-one at baseline and one immediately after pretreatment with the MOR antagonist naloxone (13 μg/kg). Whole-body PET imaging was performed on an instrument with a 142-cm axial bore. [C]carfentanil brain distribution volume ratios were determined using the occipital cortex and the visual cortex within it as reference regions. For peripheral organ distribution volume ratios, the descending aorta and proximal-extremity muscle (biceps/triceps) were used as reference regions. Naloxone blockade reduced MOR availability by 40%-50% in the caudate, putamen, thalamus, amygdala, and ventral tegmentum, brain regions known to express high levels of MORs. Women showed greater receptor occupancy in the thalamus, amygdala, hippocampus, and frontal and temporal lobes and a greater naloxone-induced reduction in thalamic MOR availability than men ( < 0.05). For determining brain MOR availability, there was less variance in the visual cortex than in the occipital cortex reference region. For peripheral MOR determination, the descending aorta reference region showed less variance than the extremity muscle, but both showed blocking effects of naloxone. [C]carfentanil whole-body PET scans are useful for understanding MOR physiology under both baseline and blocking conditions. Extra-central nervous system reference regions may be useful for quantifying radiotracers when a region devoid of binding in the central nervous system is unavailable. The long axial field of view was useful for measuring changes in the short-lived radiotracer [C]carfentanil, with and without naloxone blocking. Further research is needed to evaluate the behavioral and clinical relevance of sex differences in naloxone-MOR interactions.
μ-阿片受体(MORs)是一种G蛋白偶联受体,在大脑和身体中广泛表达。MORs对内源性阿片类物质如β-内啡肽和外源性阿片类物质如芬太尼都具有高亲和力。它们介导疼痛和奖赏,并与阿片类、可卡因及其他物质使用障碍的病理生理学有关。我们使用具有长轴向视野的仪器和MOR选择性放射性配体[C]卡芬太尼,测量了13名健康人体内MORs的全身分布情况。我们还研究了基线时以及用MOR拮抗剂纳洛酮预处理后MOR分布的性别差异。6名女性和7名男性健康受试者接受了2次[C]卡芬太尼PET成像检查——一次在基线时,一次在使用MOR拮抗剂纳洛酮(13μg/kg)预处理后立即进行。全身PET成像在一台轴向孔径为142厘米的仪器上进行。[C]卡芬太尼脑分布体积比通过将枕叶皮质及其内的视觉皮质作为参考区域来确定。对于外周器官分布体积比,降主动脉和近端肢体肌肉(肱二头肌/肱三头肌)被用作参考区域。纳洛酮阻断使尾状核、壳核、丘脑、杏仁核和腹侧被盖区(已知表达高水平MORs的脑区)的MOR可用性降低了40%-50%。女性在丘脑、杏仁核、海马体以及额叶和颞叶中表现出更高的受体占有率,并且与男性相比,纳洛酮诱导的丘脑MOR可用性降低幅度更大(P<0.05)。对于确定脑MOR可用性,视觉皮质中的变异性小于枕叶皮质参考区域。对于外周MOR测定,降主动脉参考区域的变异性小于肢体肌肉,但两者都显示出纳洛酮的阻断作用。[C]卡芬太尼全身PET扫描有助于了解基线和阻断条件下的MOR生理学。当在中枢神经系统中没有无结合的区域时,中枢神经系统外参考区域可能有助于对放射性示踪剂进行定量。长轴向视野对于测量有或没有纳洛酮阻断情况下短寿命放射性示踪剂[C]卡芬太尼的变化很有用。需要进一步研究来评估纳洛酮-MOR相互作用中性别差异的行为和临床相关性。